The Indian Drug Manufacturers’ Association (IDMA) and UL of the USA are jointly organising a seminar on “Sustaining Regulatory Compliance in the Pharma Industry” on February 4, 2014 at Hotel Grand Hyatt-Kalina, Mumbai.

The seminar brings together a unique group of global Pharma thought leaders and practicing professionals in the fields of regulatory compliance learning, organizational quality and business performance. The global thought leaders of this program will bring you the essence of US FDA best practices, what it means to be validated and 21 CFR 11 compliant, and how to translate this into the culture of Compliance and Quality through learning.

The theme of the programme is relevant and timely, and has evolved from ongoing discussions with pharma/life sciences companies, and insights gained from UL’s expertise in the global marketplace with focus on recent global attention to compliance issues and challenges in India. It solidifies UL & IDMA’s commitment for demonstrating responsible global citizenship and UL’s safety mission: “Working for a Safer World”.

The summit focuses on introducing new ideas, proven strategies and practical techniques that you can take away and implement within your company’s compliance and regulatory challenges. This also prepares your company to equip itself against audit exposure and facilitate audit readiness. This year’s group of speakers and presentations will help your organization better align learning strategies with its quality and compliance objectives.

The key focus areas of the event are Quality & Compliance Trends and Best practices: Benchmarking study by UL in Pharma Industry; How Indian Pharma can leverage best GMP and cGMP practices; What You Need to Know about Risk and Compliance for US FDA and EU Inspection; and Roadmap for Indian Pharma to reduce risks of regulatory scrutiny and creating a culture for compliance through learning.